BioCentury
ARTICLE | Distillery Therapeutics

Cancer

August 29, 2017 6:08 PM UTC

Patient sample, cell culture and mouse studies suggest inhibiting PAD2 could help treat castration-resistant prostate cancer (CRPC). In patient samples, levels of PAD2 were higher in CRPC tumors than in hormone-dependent tumors. In a human CRPC cell line, PAD2 knockdown or a PAD2 inhibitor tool compound decreased viability compared with normal PAD2 expression or vehicle, respectively, and Xtandi enzalutamide plus either PAD2 knockdown or the PAD2 inhibitor decreased cell viability compared with Xtandi alone. In a xenograft mouse model of CRPC, Xtandi plus the PAD2 inhibitor decreased tumor growth compared with either agent alone. Next steps could include identifying and testing PAD2 inhibitors in additional prostate cancer models...